8月10日，Twist Bioscience盘中上涨5.04%，报121.5046美元/股，成交额4905.15万美元。
消息面上，市场持续关注AI赋能药物发现对公司的价值重估。公司在AI驱动的DBTL工作流中承接高通量DNA合成与蛋白表达的核心"Build-Test"环节，已获得订单验证，每轮迭代驱动客户复购合成服务形成正向循环。此外，公司此前上调全年营收指引至4.56亿至4.57亿美元，Q4营收指引1.23亿至1.24亿美元，大幅高于一致预期的1.174亿美元，强劲增长预期持续支撑股价走高。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.